Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
Background and aims Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. Methods A web-based questionnaire on the use of TDM was distributed to Scandi...
Published in: | Scandinavian Journal of Gastroenterology |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2022
|
Subjects: | |
Online Access: | http://hdl.handle.net/10852/100251 https://doi.org/10.1080/00365521.2022.2108684 |
id |
ftoslouniv:oai:www.duo.uio.no:10852/100251 |
---|---|
record_format |
openpolar |
spelling |
ftoslouniv:oai:www.duo.uio.no:10852/100251 2023-05-15T16:51:40+02:00 Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia ENEngelskEnglishTherapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia Hammersbøen, Kristin Reine Jahnsen, Jørgen Brynskov, Jørn Molander, Pauliina Eberhardson, Michael Davidsdottir, Loà G. Sipponen, Taina Hjortswang, Henrik Goll, Guro Løvik Syversen, Silje Watterdal Langholz, Ebbe Jørgensen, Kristin Kaasen Steenholdt, Casper 2022-11-07T11:14:20Z http://hdl.handle.net/10852/100251 https://doi.org/10.1080/00365521.2022.2108684 EN eng NFR/328657 Hammersbøen, Kristin Reine Jahnsen, Jørgen Brynskov, Jørn Molander, Pauliina Eberhardson, Michael Davidsdottir, Loà G. Sipponen, Taina Hjortswang, Henrik Goll, Guro Løvik Syversen, Silje Watterdal Langholz, Ebbe Jørgensen, Kristin Kaasen Steenholdt, Casper . Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scandinavian Journal of Gastroenterology. 2022 http://hdl.handle.net/10852/100251 2069869 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scandinavian Journal of Gastroenterology&rft.volume=&rft.spage=&rft.date=2022 Scandinavian Journal of Gastroenterology 58 1 25 33 9 https://doi.org/10.1080/00365521.2022.2108684 Attribution-NonCommercial-NoDerivatives 4.0 International https://creativecommons.org/licenses/by-nc-nd/4.0/ CC-BY-NC-ND 0036-5521 Journal article Tidsskriftartikkel Peer reviewed PublishedVersion 2022 ftoslouniv https://doi.org/10.1080/00365521.2022.2108684 2023-02-22T23:36:46Z Background and aims Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. Methods A web-based questionnaire on the use of TDM was distributed to Scandinavian gastroenterologists via the national societies. Results In total, 297 IBD physicians prescribing biologic therapies, equally distributed between community and university hospitals, were included (response rate 42%) (Norway 118 (40%), Denmark 86 (29%), Sweden 50 (17%), Finland 33 (11%), Iceland 10 (3%)). Overall, TDM was applied during biologic therapies by 87%, and for TNF-inhibitors >90%. Among the users, reactive and proactive TDM were utilized by 90% and 63%, respectively. Danish physicians were significantly less inclined to use TDM compared to other Scandinavian countries; (58% vs 98%); OR 0.03 [0.01–0.09], p < 0.001). Reactive TDM was commonly applied at primary (74%) and secondary (99%) treatment failure. Proactive TDM was used by 80% during maintenance therapy and 56% during induction and more commonly utilized in Norway (p < 0.001), and by physicians managing >10 IBD patients/week (p = 0.005). TDM scenarios were interpreted in accord with available evidence but with discrepancies for proactive TDM. The main barriers to TDM were lack of guidelines (51%) and time lag between sampling and results (49%). TDM of thiopurines was routinely used by 87%. Conclusion TDM of biologic and thiopurine therapies has been broadly implemented into clinical practice in Scandinavia. However, physicians call for TDM guidelines detailing indications and interpretations of test results along with improved test response times. Article in Journal/Newspaper Iceland Universitet i Oslo: Digitale utgivelser ved UiO (DUO) Norway Scandinavian Journal of Gastroenterology 58 1 25 33 |
institution |
Open Polar |
collection |
Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
op_collection_id |
ftoslouniv |
language |
English |
description |
Background and aims Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. Methods A web-based questionnaire on the use of TDM was distributed to Scandinavian gastroenterologists via the national societies. Results In total, 297 IBD physicians prescribing biologic therapies, equally distributed between community and university hospitals, were included (response rate 42%) (Norway 118 (40%), Denmark 86 (29%), Sweden 50 (17%), Finland 33 (11%), Iceland 10 (3%)). Overall, TDM was applied during biologic therapies by 87%, and for TNF-inhibitors >90%. Among the users, reactive and proactive TDM were utilized by 90% and 63%, respectively. Danish physicians were significantly less inclined to use TDM compared to other Scandinavian countries; (58% vs 98%); OR 0.03 [0.01–0.09], p < 0.001). Reactive TDM was commonly applied at primary (74%) and secondary (99%) treatment failure. Proactive TDM was used by 80% during maintenance therapy and 56% during induction and more commonly utilized in Norway (p < 0.001), and by physicians managing >10 IBD patients/week (p = 0.005). TDM scenarios were interpreted in accord with available evidence but with discrepancies for proactive TDM. The main barriers to TDM were lack of guidelines (51%) and time lag between sampling and results (49%). TDM of thiopurines was routinely used by 87%. Conclusion TDM of biologic and thiopurine therapies has been broadly implemented into clinical practice in Scandinavia. However, physicians call for TDM guidelines detailing indications and interpretations of test results along with improved test response times. |
format |
Article in Journal/Newspaper |
author |
Hammersbøen, Kristin Reine Jahnsen, Jørgen Brynskov, Jørn Molander, Pauliina Eberhardson, Michael Davidsdottir, Loà G. Sipponen, Taina Hjortswang, Henrik Goll, Guro Løvik Syversen, Silje Watterdal Langholz, Ebbe Jørgensen, Kristin Kaasen Steenholdt, Casper |
spellingShingle |
Hammersbøen, Kristin Reine Jahnsen, Jørgen Brynskov, Jørn Molander, Pauliina Eberhardson, Michael Davidsdottir, Loà G. Sipponen, Taina Hjortswang, Henrik Goll, Guro Løvik Syversen, Silje Watterdal Langholz, Ebbe Jørgensen, Kristin Kaasen Steenholdt, Casper Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia |
author_facet |
Hammersbøen, Kristin Reine Jahnsen, Jørgen Brynskov, Jørn Molander, Pauliina Eberhardson, Michael Davidsdottir, Loà G. Sipponen, Taina Hjortswang, Henrik Goll, Guro Løvik Syversen, Silje Watterdal Langholz, Ebbe Jørgensen, Kristin Kaasen Steenholdt, Casper |
author_sort |
Hammersbøen, Kristin Reine |
title |
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia |
title_short |
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia |
title_full |
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia |
title_fullStr |
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia |
title_full_unstemmed |
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia |
title_sort |
therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in scandinavia |
publishDate |
2022 |
url |
http://hdl.handle.net/10852/100251 https://doi.org/10.1080/00365521.2022.2108684 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
0036-5521 |
op_relation |
NFR/328657 Hammersbøen, Kristin Reine Jahnsen, Jørgen Brynskov, Jørn Molander, Pauliina Eberhardson, Michael Davidsdottir, Loà G. Sipponen, Taina Hjortswang, Henrik Goll, Guro Løvik Syversen, Silje Watterdal Langholz, Ebbe Jørgensen, Kristin Kaasen Steenholdt, Casper . Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scandinavian Journal of Gastroenterology. 2022 http://hdl.handle.net/10852/100251 2069869 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Scandinavian Journal of Gastroenterology&rft.volume=&rft.spage=&rft.date=2022 Scandinavian Journal of Gastroenterology 58 1 25 33 9 https://doi.org/10.1080/00365521.2022.2108684 |
op_rights |
Attribution-NonCommercial-NoDerivatives 4.0 International https://creativecommons.org/licenses/by-nc-nd/4.0/ |
op_rightsnorm |
CC-BY-NC-ND |
op_doi |
https://doi.org/10.1080/00365521.2022.2108684 |
container_title |
Scandinavian Journal of Gastroenterology |
container_volume |
58 |
container_issue |
1 |
container_start_page |
25 |
op_container_end_page |
33 |
_version_ |
1766041790072225792 |